Rovida Advisors Inc. Eli Lilly & CO Transaction History

Rovida Advisors Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$234.69 - $291.66 $51.5 Million - $64 Million	-219,500 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$136.42 - $164.18 $29.9 Million - $36 Million	219,500 New	219,500 $36 Million
Q1 2020 May 13, 2020	SELL	$119.05 - $147.35 $30.1 Million - $37.2 Million	-252,600 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$106.79 - $116.16 $4.67 Million - $5.08 Million	-43,700 Reduced 14.75%	252,600 $28.2 Million
Q3 2017 Nov 09, 2017	BUY	$77.07 - $85.54 $22.8 Million - $25.3 Million	296,300	296,300 $25.3 Million

4,028

739M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $690B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Rovida Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Rovida Advisors Inc. with notifications on news.